Although clinical trials using gefitinib as a monotherapy for breast cancer have exhibited unsatisfactory results, immunohistochemical analysis of post-treatment breast tumors has revealed complete inhibition of EGFR phosphorylation (Baselga et al., 2005). The gene discussed is EGFR; the disease is breast cancer.